# Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study

**Authors:** Zhengwei Tan, Yuechao Zhao, Huijin Hu, Qinghong Yu, Yu Zhang, Tonglin Hu, Dijiong Wu, Baodong Ye, Wenbin Liu

PMC · DOI: 10.1007/s00277-026-06869-6 · Annals of Hematology · 2026-03-18

## TL;DR

This study compares outcomes of early versus delayed stem cell transplants for severe aplastic anemia and finds that earlier transplants reduce virus reactivation risks.

## Contribution

The study provides evidence that early allogeneic stem cell transplantation improves outcomes by reducing CMV reactivation in severe aplastic anemia patients.

## Key findings

- Early allo-HSCT significantly reduces CMV reactivation compared to delayed transplantation.
- No significant differences in graft-versus-host disease or survival rates between early and delayed groups.
- Subgroup analyses show better survival for younger patients and those with matched donors.

## Abstract

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is the only curative therapy for severe aplastic anemia (SAA), yet the prognostic impact of the diagnostic-to-transplant interval on first allo-HSCT remains contentious. To determine whether a waiting time > 1 year from diagnosis to first allo-HSCT compromises engraftment, virus reactivation, GVHD, OS and GRFS in SAA. A single-center retrospective cohort study of 255 consecutive SAA patients receiving their first allo-HSCT between 2018 and 2025. After 1:2 propensity-score matching (caliiper 0.2), patients were stratified into Early (≤ 1 year, n = 170) and Delayed (> 1 year, n = 85) groups. Baseline characteristics were well balanced. The Early group exhibited a significantly lower CMV reactivation rate (24.1% vs. 40.0%, P = 0.008). No significant differences were observed in grade II-IV aGVHD, cGVHD, 5-year OS or GRFS. Subgroup analyses demonstrated superior survival among patients aged ≤ 40 years, those with MSD donors and received FABT-based regimen. Early allo-HSCT improves transplant outcomes in SAA by reducing CMV reactivation, especially in very severe cases. Eligible patients should be referred promptly and transplanted without delay.

## Full-text entities

- **Genes:** CABIN1 (calcineurin binding protein 1) [NCBI Gene 23523] {aka CAIN, KB-318B8.7, PPP3IN}, CD34 (CD34 molecule) [NCBI Gene 947], SAA [NCBI Gene 6287]
- **Diseases:** multi-organ failure (MESH:D009102), opportunistic infections (MESH:D009894), cGVHD (MESH:D000092122), hematopoietic failure (MESH:D051437), EBV-reactivation (MESH:D020031), inflammatory (MESH:D007249), MSD (MESH:C538465), GRFS (MESH:D006086), NE (MESH:C564275), severe (MESH:D045169), bone marrow hematopoietic failure (MESH:D000080983), CMV reactivation (MESH:D000085343), death (MESH:D003643), iron overload (MESH:D019190), AA (MESH:C566236), infection (MESH:D007239), bleeding (MESH:D006470), Aplastic Anemia (MESH:D000741), CMV (MESH:D003586), cytopenia (MESH:D006402), toxicities (MESH:D064420), grade III (MESH:D001254)
- **Chemicals:** MTX (MESH:D008727), FK506 (MESH:D016559), MMF (MESH:D009173), CsA (MESH:D016572), CTX (MESH:D003520), Bu (MESH:D002066), BuCy (-), TT (MESH:D013852), Fludarabine (MESH:C024352)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12995939/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12995939/full.md

---
Source: https://tomesphere.com/paper/PMC12995939